A phase 2 trial investigating the effects of the angiotensin II type 2 receptor agonist C21 in systemic sclerosis-related Raynaud’s

202217 citationsJournal Articlehybrid Open Access

Authors

ClinicalTrials.gov, https://clinicaltrials.gov, NCT04388176.

Good health and well-being

Published in: Lara D. Veeken

Volume 62, Issue 2, pp. 824-828

Field-Weighted Citation Impact: 2.04